Novel In Vitro Nail Models for Topical Development
September 1, 2018
MedPharm has validated proprietary models for measuring the permeation, penetration and efficacy of customer’s products into and across the nail
In a recent paper, published in Expert Opinion on Drug Delivery, MedPharm discuss the various in vitro models that have been developed. Our models allow for the study of the mechanisms of ungual drug absorption and formulation efficacy to be assessed. Inside you can learn about the TurChub® zone of inhibition, ChubTur® nail permeation, TurSh nail penetration and RoMar antifungal efficacy models.
MedPharm has used its development expertise on formulations for nails to support clients on two occasions to obtain regulatory approval with in vitro bioequivalence testing only. With clinical trials being a costly and high-risk approach to generic approval, the described novel in vitro screening and performance testing techniques offer a de-risked and less-expensive route to market.
Please click here to gain access to the paper.
MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognised for their scientific rigour by regulators and investors. MedPharm has fully established R&D centres in the USA and UK and has its global HQ in Guildford, UK.